Vetoquinol SA

V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
  • TickerVETO
  • ISINFR0004186856
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alfred Glaser ...
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hana Maalej
  • Nicolas Thorez
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 17/10/2019

...

Christophe-Raphaël Ganet

Vetoquinol : Bon CA T3 dans l’ensemble, mais encore du contraste dans le détail du portefeuille – OC ajusté de 59 € à 60.5 €

>T3 consistant (+11% et +5.3% à données comparables) - Le CA T3 ressort à 100.2 M€, en hausse de 11% (+9.4% à tcc et +5.3% à ptcc). A 9 mois, le CA atteint 283.9 M€, +5.9% (+2.1% lfl) avec Amériques, +11.3% à données publiées, +4.0% en Europe et +1.0% en Asie/Pacifique.En termes qualitatifs, le communiqué ajoute : i/ la structure financière reste solide (rappel : 36 M€ de cash net, à fin juin 2019) ; ii/ Vétoquinol continue d’étudier des dossiers d’acquisition(s)...

VETOQUINOL sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of VETOQUINOL (FR), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 1 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 8, 2019, the closing price was EUR 58.80 and its potential was estimated at EUR 66.06.

1 director sold

A director at Vetoquinol sold 1,300 shares at 60.322EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Christophe-Raphaël Ganet

Vetoquinol : Bon CA T3 dans l’ensemble, mais encore du contraste dans le détail du portefeuille – OC ajusté de 59 € à 60.5 €

>T3 consistant (+11% et +5.3% à données comparables) - Le CA T3 ressort à 100.2 M€, en hausse de 11% (+9.4% à tcc et +5.3% à ptcc). A 9 mois, le CA atteint 283.9 M€, +5.9% (+2.1% lfl) avec Amériques, +11.3% à données publiées, +4.0% en Europe et +1.0% en Asie/Pacifique.En termes qualitatifs, le communiqué ajoute : i/ la structure financière reste solide (rappel : 36 M€ de cash net, à fin juin 2019) ; ii/ Vétoquinol continue d’étudier des dossiers d’acquisition(s)...

Alain William ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Florent Laroche-Joubert
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Matthias Desmarais
  • Nicolas David
  • Nicolas Thorez
  • Olivier Lebrun
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 07/26/2019

...

Christophe-Raphaël Ganet

Vetoquinol : Q2 2019 sluggish – H1 margin lower than we anticipated – Downward revision to our estimates – Target price: € 59 vs € 60

>Q2 sales: +2.9% - Fall in operating margin of nearly 180bp - Q2 sales reached € 92.8m, up +2.9%. External growth in Brazil generated growth of 2.7%; the positive currency impact (+1.6%) offset the decline seen in Asia/Pacific.In H1 2019, underlying EBIT came out at € 17.9m, down 12.9% compared with the same period last year; 9.7% of sales.Vétoquinol posted positive net cash at end-June 2019 of € 36.4m after factoring in the application of IFRS 16 (impact: +...

Alain William ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Florent Laroche-Joubert
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Matthias Desmarais
  • Nicolas David
  • Nicolas Thorez
  • Olivier Lebrun
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 26/07/2019

...

Christophe-Raphaël Ganet

Vetoquinol : CA T2 2019 poussif – Marge S1 inférieure à notre attente – Révision en baisse de nos estimations – OC : 59 € vs 60 €

>CA T2: +2.9% - Baisse de la MOP de près de 180 pb - Les ventes du T2 ont atteint 92.8 M€, soit +2.9%. La croissance externe au Brésil génère une croissance de 2.7% ; l’impact positif de change (+1.6%) compense le repli observé sur le territoire Asie/Pacifique.Sur le S1 2019, le ROC se situe à 17.9 M€, en repli de 12.9% par rapport à la même période de l’exercice précédent ; il s’établit à 9.7% du CA.Vétoquinol affiche, à fin juin 2019, une situation de trés...

1 director sold

A director at Vetoquinol sold 1,300 shares at 60.322EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Alfred Glaser ...
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hana Maalej
  • Nicolas Thorez
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 17/10/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hela Zarrouk
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 04/18/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hela Zarrouk
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 18/04/2019

...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 03/22/2019

...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 22/03/2019

...

VETOQUINOL sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of VETOQUINOL (FR), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 1 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 8, 2019, the closing price was EUR 58.80 and its potential was estimated at EUR 66.06.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Dechra Pharmaceuticals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Dechra Pharmaceuticals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Dechra Pharmaceuticals PLC since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

MarketLine Department

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Onxeo SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This ...

Florian Béchaz

Vétoquinol S.A. - Assemblée Générale des actionnaires du 21 mai 2019

Proxinvest attire l'attention des actionnaires sur les points suivants : Tout d'abord, notons que le Conseil d'administration de la société est largement composé par la famille Frechin, actionnaire de contrôle, qui est représentée par 4 sièges sur 8 (50%). Par ailleurs, Proxinvest regrette que la société maintienne la possibilité de l'usage de ses délégations financières en période d'offre publique, ce qui n'est pas favorable aux intérêts des actionnaires puisque cela peut être considéré comme la mise en place d'un arsenal anti-OPA. Enfin, la communication de la société concernant les rémuné...

Jehanne Leroy

Proxy Report - 29/05/2018

Proxinvest attire l'attention des actionnaires sur les points suivants : Tout d'abord, notons que le Conseil d'administration de la société est largement dominé par la famille Frechin, actionnaire de contrôle, qui est représentée par 5 sièges sur 9 (55,6%). Par ailleurs, Proxinvest regrette que la société maintienne la possibilité de l'usage de ses délégations financières en période d'offre publique, ce qui n'est pas favorable aux intérêts des actionnaires puisque cela peut être considéré comme la mise en place d'un arsenal anti-OPA. Enfin, la communication de la société concernant les rémun...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch